Study of CM336 and Isatuximab for new multiple myeloma with kidney problems
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, CM336 and Isatuximab, for people newly diagnosed with multiple myeloma that has caused kidney damage. The goal is to see if this treatment can help control the myeloma while also addressing the kidney issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been newly diagnosed with multiple myeloma that is causing symptoms and has affected your kidneys.
- Your kidney function is reduced, with a specific measure (eGFR) below 40 mL/min, and the kidney problem is likely due to myeloma casts.
- You have measurable signs of myeloma in your blood or urine, like a certain level of M-protein or abnormal light chains.
- You are in generally good health aside from the myeloma, with adequate blood counts and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma in patients who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control myeloma and improve survival.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.